open access: Letter: Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies

Link to Letter

 REFERENCES (original article)

1. ↵
   1. Korn EL,
   2. Freidlin B,
   3. Abrams JS

   (2011) Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 29:2439–2442.

   Abstract/FREE Full Text

full free access: Why Randomized Surgical Oncology Trials Are So Scarce — J. Natl. Cancer Inst.

abstract: Hormone prevention strategies for breast, endometrial and ovarian cancers

"Prospective, randomized trials, designed to control for all known variables, are mandatory to fully assess the potential for hormonal chemoprevention in breast, endometrial and ovarian cancers."

The Challenge of Rational Development of Complex Natural Products as Cancer Therapeutics -- White, 10.1093/jnci/djq196 -- JNCI Journal of the National Cancer Institute

med blog: You Shouldn't Call Something a Breakthrough When It's in a Phase I Trial

Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations -- JCO

"Therefore, the Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This international collaboration will also facilitate the future planning of clinical trials that can address essential questions in the treatment of male breast cancer."

Thomas J. Herzog, MD, Columbia University College of Physicians and Surgeons talks about liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced malignancy/GOG reference to trials

Note: This is a repost of the video. Dr Herzog speaks briefly about the direction of GOG trials including the numerous drug combinations and trying to assess the best approaches.

NIH Foundation, Biomarkers Consortium Team on Cancer Trials (breast) GenomeWeb

"...The clinical trials will use Agendia's MammaPrint test and TargetPrint Her2 risk scores, as well as estrogen receptor and progesterone receptor status information and MRI to help determine eligibility for the trial.
The large-scale trial will involve more than twenty university hospitals and medical centers spread around the country, including The University of Texas MD Anderson Cancer Center, the Mayo Clinic in Arizona and Minnesota, the Fred Hutchinson Cancer Research Center, and a number of others...."

Journal of Experimental & Clinical Cancer Research | Full text | Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research

Note: there is a specific section on ovarian cancer

Background: Viscum album L. extracts (VAE, European mistletoe) are a widely used medicinal plant extract in gynaecological and breast-cancer treatment.  Conclusion: VAE shows some positive effects in breast and gynaecological cancer. More research into clinical efficacy is warranted.